Axovant Announces Positive 12-month Data on AXO-Lenti-PD and Provides Updates Across Gene Therapy Pipeline Programs
January 13, 2020 06:30 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological...
Axovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 Gangliosidosis
December 19, 2019 17:40 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which a single...
Axovant Announces Amendment to Credit Facility with Hercules Capital
December 03, 2019 07:00 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Dec. 03, 2019 (GLOBE NEWSWIRE) -- New loan amendment reduces loan obligation by 50% without penalty, eliminates minimum cash covenant, and extends interest-only...
Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis
November 18, 2019 07:30 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the...
Axovant Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2019
November 08, 2019 08:00 ET
|
Axovant Sciences Ltd.
First evidence of clinical stabilization in two children with Tay-Sachs disease that received AXO-AAV-GM2 presented at ESGCT in October 2019Continued enrollment of patients in AXO-AAV-GM1...
Axovant Gene Therapies Announces Investor Conference Presentations for the Remainder of 2019
November 05, 2019 08:00 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that...
Axovant Gene Therapies Announces Upcoming Presentations at the European Society of Gene and Cell Therapy 27th Annual Congress
October 10, 2019 08:00 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced...
Axovant Gene Therapies to Present at 2019 Cell & Gene Meeting on the Mesa
September 25, 2019 16:05 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag Meswani,...